Document is current
Any future updates will be listed below
-
Authors
Chisholm, Christen G. https://orcid.org/0000-0002-3057-7113
Bartlett, Rachael https://orcid.org/0000-0002-9199-1326
Brown, Mikayla L. https://orcid.org/0000-0002-3464-3480
Proctor, Emma-Jayne
Farrawell, Natalie E.
Gorman, Jody
Delerue, Fabien https://orcid.org/0000-0001-7944-2108
Ittner, Lars M.
Vine-Perrow, Kara L. https://orcid.org/0000-0001-6871-1149
Ecroyd, Heath https://orcid.org/0000-0001-7574-0044
Cashman, Neil R. https://orcid.org/0000-0002-0080-1006
Saunders, Darren N. https://orcid.org/0000-0003-0924-0513
McAlary, Luke
Lum, Jeremy S. https://orcid.org/0000-0002-2133-9308
Yerbury, Justin J.
-
Funding
Funding for this research was provided by:
FightMND in the form of Drug Development Grants (DDG-137). Motor Neuron Disease Research Australia
- License Information
-
More Information
Article History
Received: 20 February 2025
Accepted: 13 October 2025
First Online: 10 November 2025
Competing interests
: N.R.C., C.C.G. and J.J.Y. are named inventors on a provisional patent application (PCT/CA2024/050200) filed by the University of British Columbia and the University of Wollongong and assigned to ProMIS Neurosciences, pertaining to sequences of antibody and ubiquitin ligase fusion proteins for misfolded superoxide dismutase 1. N.R.C. is the Chief Scientific Officer of ProMIS Neurosciences. N.R.C. has received consultation compensation from ProMIS and possesses ProMIS stock and stock options. L.M.I. is the Chief Scientific & Medical Officer, founder and shareholder of Celosia Therapeutics. All other authors declare that they have no competing interests with the contents of this article.
